GPCM
ORTX

Granite Point Capital Management’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Granite Point Capital Management’s Portfolio ORTX Stock Details ORTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,000
Closed -$700K – 97
2019
Q2 		$700K Buy
+5,000
New +$878K 0.05% 70

Other funds holding ORTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Granite Point Capital Management's ORTX Position: Q3 2019 in Review

Granite Point Capital Management sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q3 2019, closing a stake of 5,000 shares — an estimated $700K sold.

Granite Point Capital Management first reported a position in ORTX in Q2 2019 and held it in 1 quarter. The position peaked at $700K in Q2 2019. 62 funds tracked by Wall St. Rank hold ORTX as of Q3 2019.

  • Granite Point Capital Management reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q3 2019 after selling out during the quarter.
  • Granite Point Capital Management sold 5,000 Orchard Therapeutics plc American Depositary Shares shares in Q3 2019, an estimated $700K.
  • Granite Point Capital Management first reported a position in Orchard Therapeutics plc American Depositary Shares in Q2 2019 and held it in 1 quarter.
  • Granite Point Capital Management's Orchard Therapeutics plc American Depositary Shares position peaked at $700K in Q2 2019.
  • 62 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q3 2019.

Based on Granite Point Capital Management's 13F filing for Q3 2019, filed 30 Oct 2019.